Skip to main content
Erschienen in: Annals of Hematology 8/2015

01.08.2015 | Original Article

Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia

verfasst von: Miguel A. Sanz, Pau Montesinos, María F. Casale, Joaquín Díaz-Mediavilla, Santiago Jiménez, Isolda Fernández, Pascual Fernández, José González-Campos, José D. González, Pilar Herrera, Elena de Lisa, Teresa Olave, Rafael Rojas, Olga Salamero, María J. Sayas, Antonio Pellicer, Alfredo Perales

Erschienen in: Annals of Hematology | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

The management of pregnant women with acute promyelocytic leukemia (APL) is a challenge with limited evidence-based information available. We are reporting a series of 14 consecutive pregnant women with APL who were registered in the PETHEMA Data Centre between 1996 and 2012. APL was diagnosed during early pregnancy in five women, late pregnancy in seven, and two additional patients after delivery in an extremely poor clinical condition (pulmonary and cerebral hemorrhage). Eleven of the 12 patients eligible for induction therapy with all-trans retinoic acid and idarubicin achieved complete remission (CR 92 %) and are still in the first CR. All early pregnancies ended in abortion (four induced and one spontaneous), with four of them achieving CR. Eight of nine women in late pregnancy delivered a healthy infant (six cesarean section and two vaginal delivery). All eight babies developed normally. Our results confirm a high cure rate for pregnant women with APL who received all-trans retinoic acid and idarubicin for induction therapy, and an excellent outcome for babies when the disease is diagnosed during late pregnancy.
Literatur
1.
Zurück zum Zitat Yang D, Hladnik L (2009) Treatment of acute promyelocytic leukemia during pregnancy. Pharmacotherapy 29:709–724PubMedCrossRef Yang D, Hladnik L (2009) Treatment of acute promyelocytic leukemia during pregnancy. Pharmacotherapy 29:709–724PubMedCrossRef
2.
Zurück zum Zitat Sanz MA, Martín G, Rayon C et al (1999) A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 94:3015–3021PubMed Sanz MA, Martín G, Rayon C et al (1999) A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 94:3015–3021PubMed
3.
Zurück zum Zitat Sanz MA, Martín G, González M et al (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103:1237–1243PubMedCrossRef Sanz MA, Martín G, González M et al (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103:1237–1243PubMedCrossRef
4.
Zurück zum Zitat Sanz MA, Montesinos P, Rayón C et al (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115:5137–5146PubMedCrossRef Sanz MA, Montesinos P, Rayón C et al (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115:5137–5146PubMedCrossRef
5.
Zurück zum Zitat la Serna de J, Montesinos P, Vellenga E et al (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395–3402CrossRef la Serna de J, Montesinos P, Vellenga E et al (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395–3402CrossRef
6.
Zurück zum Zitat Montesinos P, Bergua JM, Vellenga E et al (2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113:775–783PubMedCrossRef Montesinos P, Bergua JM, Vellenga E et al (2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113:775–783PubMedCrossRef
7.
Zurück zum Zitat Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642–4649PubMedCrossRef Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642–4649PubMedCrossRef
8.
Zurück zum Zitat Frankel SR, Eardley A, Heller G et al (1994) All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 120:278–286PubMedCrossRef Frankel SR, Eardley A, Heller G et al (1994) All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 120:278–286PubMedCrossRef
9.
Zurück zum Zitat Sanz MA, Lo-Coco F, Martín G et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253PubMed Sanz MA, Lo-Coco F, Martín G et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253PubMed
11.
Zurück zum Zitat Alegre A, Chunchurreta R, Rodriguez-Alarcon J et al (1982) Successful pregnancy in acute promyelocytic leukemia. Cancer 49:152–153PubMedCrossRef Alegre A, Chunchurreta R, Rodriguez-Alarcon J et al (1982) Successful pregnancy in acute promyelocytic leukemia. Cancer 49:152–153PubMedCrossRef
12.
Zurück zum Zitat Lin CP, Huang MJ, Liu HJ et al (1996) Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. Am J Hematol 51:251–252PubMedCrossRef Lin CP, Huang MJ, Liu HJ et al (1996) Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. Am J Hematol 51:251–252PubMedCrossRef
13.
Zurück zum Zitat Siu BL, Alonzo MR, Vargo TA, Fenrich AL (2002) Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy. Int J Gynecol Cancer 12:399–402PubMedCrossRef Siu BL, Alonzo MR, Vargo TA, Fenrich AL (2002) Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy. Int J Gynecol Cancer 12:399–402PubMedCrossRef
14.
Zurück zum Zitat Simone MD, Stasi R, Venditti A et al (1995) All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia. Leukemia 9:1412–1413PubMed Simone MD, Stasi R, Venditti A et al (1995) All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia. Leukemia 9:1412–1413PubMed
15.
Zurück zum Zitat Ebert U, Löffler H, Kirch W (1997) Cytotoxic therapy and pregnancy. Pharmacol Ther 74:207–220PubMed Ebert U, Löffler H, Kirch W (1997) Cytotoxic therapy and pregnancy. Pharmacol Ther 74:207–220PubMed
16.
Zurück zum Zitat Requena A, Velasco JG, Pinilla J, Gonzalez-Gonzalez A (1995) Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases. Eur J Obstet Gynecol Reprod Biol 63:139–141PubMedCrossRef Requena A, Velasco JG, Pinilla J, Gonzalez-Gonzalez A (1995) Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases. Eur J Obstet Gynecol Reprod Biol 63:139–141PubMedCrossRef
17.
Zurück zum Zitat Delgado-Lamas JL, Garcés-Ruiz OM (2000) Malignancy: case report: acute promyelocytic leukemia in late pregnancy. Successful treatment with all-trans-retinoic acid (ATRA) and chemotherapy. Hematology 4:415–418PubMed Delgado-Lamas JL, Garcés-Ruiz OM (2000) Malignancy: case report: acute promyelocytic leukemia in late pregnancy. Successful treatment with all-trans-retinoic acid (ATRA) and chemotherapy. Hematology 4:415–418PubMed
18.
Zurück zum Zitat Consoli U, Figuera A, Milone G et al (2004) Acute promyelocytic leukemia during pregnancy: report of 3 cases. Int J Hematol 79:31–36PubMedCrossRef Consoli U, Figuera A, Milone G et al (2004) Acute promyelocytic leukemia during pregnancy: report of 3 cases. Int J Hematol 79:31–36PubMedCrossRef
19.
Zurück zum Zitat Chelghoum Y, Vey N, Raffoux E et al (2005) Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. Cancer 104:110–117PubMedCrossRef Chelghoum Y, Vey N, Raffoux E et al (2005) Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. Cancer 104:110–117PubMedCrossRef
Metadaten
Titel
Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia
verfasst von
Miguel A. Sanz
Pau Montesinos
María F. Casale
Joaquín Díaz-Mediavilla
Santiago Jiménez
Isolda Fernández
Pascual Fernández
José González-Campos
José D. González
Pilar Herrera
Elena de Lisa
Teresa Olave
Rafael Rojas
Olga Salamero
María J. Sayas
Antonio Pellicer
Alfredo Perales
Publikationsdatum
01.08.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 8/2015
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-015-2372-5

Weitere Artikel der Ausgabe 8/2015

Annals of Hematology 8/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.